Search
Aligos Therapeutics Inc
ALGSAdd to Watchlist
5.650USD
-0.040-0.70%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
34.96MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Aligos Therapeutics Inc is 8.40, ranking 126 out of 389 in the Biotechnology & Medical Research industry. The average price target is 55.00, with a high of 175.00 and a low of 36.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
59.667
Target Price
+948.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Aligos Therapeutics Inc
ALGS
7
Beigene Ltd
ONC
27
Ionis Pharmaceuticals Inc
IONS
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Aligos Therapeutics Inc's expected revenue for the next quarter?
Aligos Therapeutics Inc's expected revenue is 17.35M.
What is Aligos Therapeutics Inc's price target?
Analysts forecast that Aligos Therapeutics Inc's price target is USD 55.00, with the highest forecast at USD 175.00 and the lowest forecast at USD 36.00.
How have Aligos Therapeutics IncALGS's recent earnings per share performed?
The market expectation was USD -2.21, while Aligos Therapeutics IncALGS's earnings per share (EPS) for the previous quarter was USD -1.91. EPS for the next quarter is expected at USD -1.07.
What is the analyst rating for Aligos Therapeutics Inc?
Based on the ratings of Aligos Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
